← Oncology Approval Tracker

FDA DECISION ·

Opdivo

nivolumab · Bristol Myers Squibb

FDA approvalNew or expanded indicationMelanoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

The single-agent unresectable or metastatic melanoma indication expanded to patients aged 12 or older.

LAMPGEN ANALYSIS

Why it matters

The supplement made nivolumab monotherapy available to an adolescent population under the label.

What research teams should watch

Confirm age and weight, and distinguish the single-agent indication from the ipilimumab combination.

PRIMARY RECORDS

Sources